Understanding how KEAP1 mutations affect kidney cancer risk
Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
This study is looking at how changes in a specific gene called KEAP1 might affect kidney cancer, with the hope of finding better ways to screen for and treat this disease, especially for those who may be more likely to get it because of their family history.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10875299 on NIH RePORTER |
What this research studies
This research investigates the role of KEAP1 mutations in renal cell carcinoma (RCC), a type of kidney cancer that often has a poor prognosis when diagnosed late. The project aims to identify how these genetic mutations contribute to the development and progression of RCC, which could lead to improved screening and targeted treatment options for patients. The research involves a combination of genetic analysis and clinical assessments to better understand the implications of KEAP1 mutations in cancer susceptibility. By focusing on hereditary aspects of RCC, the study seeks to enhance knowledge about genetic predispositions and their impact on patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of renal cell carcinoma or those diagnosed with RCC at a young age.
Not a fit: Patients with renal cell carcinoma who do not have KEAP1 mutations or a family history of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better screening methods and personalized treatment strategies for patients at risk of renal cell carcinoma.
How similar studies have performed: Previous research has shown promising results in understanding genetic mutations in various cancers, suggesting that this approach could yield valuable insights into renal cell carcinoma as well.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Carlo, Maria — Sloan-Kettering Inst Can Research
- Study coordinator: Carlo, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.